What is Wedbush’s Forecast for VIGL FY2029 Earnings?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities researchers at Wedbush issued their FY2029 EPS estimates for Vigil Neuroscience in a research note issued to investors on Thursday, March 13th. Wedbush analyst L. Chico anticipates that the company will post earnings of $1.40 per share for the year. Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

Other equities analysts have also recently issued reports about the company. William Blair initiated coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating for the company. HC Wainwright dropped their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience presently has an average rating of “Buy” and a consensus target price of $16.25.

Vigil Neuroscience Stock Down 2.0 %

Shares of VIGL opened at $1.98 on Monday. The company has a 50-day moving average price of $2.34 and a two-hundred day moving average price of $2.77. The stock has a market cap of $80.94 million, a price-to-earnings ratio of -0.96 and a beta of 1.82. Vigil Neuroscience has a 12 month low of $1.49 and a 12 month high of $6.06.

Hedge Funds Weigh In On Vigil Neuroscience

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC raised its holdings in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after buying an additional 8,358 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Vigil Neuroscience in the fourth quarter worth about $83,000. Barclays PLC raised its stake in shares of Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after acquiring an additional 19,436 shares during the last quarter. Northern Trust Corp lifted its position in shares of Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after purchasing an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after purchasing an additional 49,000 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.